<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="7112">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00955617</url>
  </required_header>
  <id_info>
    <org_study_id>DGD-44-052</org_study_id>
    <nct_id>NCT00955617</nct_id>
  </id_info>
  <brief_title>DOTAREM®-Enhanced MRA Compared to GADOVIST®-Enhanced MRA in Patients With Abdominal or Lower Limb Arterial Diseases</brief_title>
  <official_title>Intra-individual Efficacy Evaluation of DOTAREM®-Enhanced MRA Compared to GADOVIST®-Enhanced MRA in the Diagnosis of Clinically Significant Abdominal or Lower Limb Arterial Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guerbet</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guerbet</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is an intra-individual comparison of DOTAREM®-enhanced MRA and GADOVIST®-enhanced
      MRA in the diagnosis of clinically significant abdominal or lower limb arterial diseases.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Overall Image Quality of MRA Images</measure>
    <time_frame>MRA examination</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of images quoted with excellent and more than adequate quality in each group.
Image quality will be assessed on a 5-point scale:
Excellent
More than adequate
Adequate
Less than adequate
Non-diagnostic
Each image is analysed by 4 readers.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Diagnostic Confidence</measure>
    <time_frame>MRA examination</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of High/Excellent diagnostic confidence. Level of diagnostic confidence assessed on a 5-point scale by patient: nil, poor, moderate, high, excellent.
Each image is analysed by 4 readers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Signal Intensity</measure>
    <time_frame>MRA examination</time_frame>
    <safety_issue>No</safety_issue>
    <description>Signal to Noise ratio (SNR): SNR = SIa /NO SIa is the signal intensity measured in the ROI positioned in the artery. NO is noise defined as the standard deviation (SD) of signal intensity measured in the subtraction image (of the two non-enhanced scans) at the same location as the arterial ROI is to be measured.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <arm_group>
    <arm_group_label>Dotarem / Gadovist</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Contrast-enhanced MRA - Imaging examination contrast enhanced-MRA first with Dotarem in period 1 then with Gadovist in period 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gadovist / Dotarem</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Contrast-enhanced MRA - Imaging examination contrast enhanced-MRA first with Gadovist in period 1 then with Dotarem in period 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Contrast-enhanced MRA - Imaging examination</intervention_name>
    <description>Administration of 0.1 mmol/kg of contrast product (Dotarem and Gadovist)</description>
    <arm_group_label>Dotarem / Gadovist</arm_group_label>
    <arm_group_label>Gadovist / Dotarem</arm_group_label>
    <other_name>Dotarem-enhanced MRA</other_name>
    <other_name>Gadovist-enhanced MRA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female or male, aged ≥ 18 years

          -  Patient suffering from Peripheral Arterial Occlusive Disease (PAOD) stage II or III.

        Exclusion Criteria:

          -  Patients with severely impaired renal function with an eGFR (MDRD) &lt; 50ml/min (eGFR
             based on recent serum creatinine and MDRD formula - younger than 21 days).

          -  Patient planned to undergo therapeutic intervention in the vessels of interest
             between the two MRA procedures.

          -  Patient who had a major cardiovascular event within 30 days prior to the inclusion.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guerbet</last_name>
    <role>Study Director</role>
    <affiliation>Guerbet</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Guerbet</name>
      <address>
        <city>Roissy CDG Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <lastchanged_date>October 5, 2012</lastchanged_date>
  <firstreceived_date>August 6, 2009</firstreceived_date>
  <firstreceived_results_date>August 8, 2012</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dotarem</keyword>
  <keyword>Gadovist</keyword>
  <keyword>Peripheral arterial disease</keyword>
  <keyword>MRA</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Contrast Media</mesh_term>
    <mesh_term>Gadobutrol</mesh_term>
    <mesh_term>Gadoterate meglumine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Dotarem Then Gadovist</title>
          <description>Cross over administration, patient received first Dotarem enhanced-MRA (MRA1) and then Gadovist enhanced-MRA (MRA2)</description>
        </group>
        <group group_id="P2">
          <title>Gadovist Then Dotarem</title>
          <description>Cross over administration: patient received first Gadovist enhanced-MRA (MRA1) and then Dotarem enhanced-MRA (MRA2)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First MRA (Between Day0 and Day21)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second MRA (Between Day 1 and Day 51)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>technical incident</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>conventional angiography</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Patients</title>
          <description>All Patients received both product Dotarem and Gadovist during 2 enhanced-MRA. Demographic analysis was performed on the global population.</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="20"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="13"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="7"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="61.5" spread="8.1"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="5"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="15"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Germany</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="20"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Image Quality of MRA Images</title>
        <description>Number of images quoted with excellent and more than adequate quality in each group.
Image quality will be assessed on a 5-point scale:
Excellent
More than adequate
Adequate
Less than adequate
Non-diagnostic
Each image is analysed by 4 readers.</description>
        <time_frame>MRA examination</time_frame>
        <safety_issue>No</safety_issue>
        <population>descriptive and pilot study, no number of participants calculation performed</population>
        <group_list>
          <group group_id="O1">
            <title>Dotarem</title>
            <description>Evaluation performed on Dotarem enhanced MRA images</description>
          </group>
          <group group_id="O2">
            <title>Gadovist</title>
            <description>Evaluation performed on Gadovist enhanced MRA images</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="14"/>
                  <measurement group_id="O2" value="14"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of cases (4 evaluations per image) analyzed</title>
            <units>cases (4 evaluations per image)</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="56"/>
                  <measurement group_id="O2" value="56"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Overall Image Quality of MRA Images</title>
            <description>Number of images quoted with excellent and more than adequate quality in each group.
Image quality will be assessed on a 5-point scale:
Excellent
More than adequate
Adequate
Less than adequate
Non-diagnostic
Each image is analysed by 4 readers.</description>
            <units>Images</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="56"/>
                  <measurement group_id="O2" value="48"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Diagnostic Confidence</title>
        <description>Number of High/Excellent diagnostic confidence. Level of diagnostic confidence assessed on a 5-point scale by patient: nil, poor, moderate, high, excellent.
Each image is analysed by 4 readers.</description>
        <time_frame>MRA examination</time_frame>
        <safety_issue>No</safety_issue>
        <population>Descriptive study - No calculation</population>
        <group_list>
          <group group_id="O1">
            <title>Dotarem</title>
            <description>Evaluation performed on Dotarem enhanced MRA images</description>
          </group>
          <group group_id="O2">
            <title>Gadovist</title>
            <description>Evaluation performed on Gadovist enhanced MRA images</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="14"/>
                  <measurement group_id="O2" value="14"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of cases (4 evaluations per image) analyzed</title>
            <units>cases (4 evaluations per image)</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="56"/>
                  <measurement group_id="O2" value="56"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Diagnostic Confidence</title>
            <description>Number of High/Excellent diagnostic confidence. Level of diagnostic confidence assessed on a 5-point scale by patient: nil, poor, moderate, high, excellent.
Each image is analysed by 4 readers.</description>
            <units>Images</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="55"/>
                  <measurement group_id="O2" value="50"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Signal Intensity</title>
        <description>Signal to Noise ratio (SNR): SNR = SIa /NO SIa is the signal intensity measured in the ROI positioned in the artery. NO is noise defined as the standard deviation (SD) of signal intensity measured in the subtraction image (of the two non-enhanced scans) at the same location as the arterial ROI is to be measured.</description>
        <time_frame>MRA examination</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Dotarem</title>
            <description>Evaluation performed on Dotarem enhanced MRA images</description>
          </group>
          <group group_id="O2">
            <title>Gadovist</title>
            <description>Evaluation performed on Gadovist enhanced MRA images</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="14"/>
                  <measurement group_id="O2" value="14"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Signal Intensity</title>
            <description>Signal to Noise ratio (SNR): SNR = SIa /NO SIa is the signal intensity measured in the ROI positioned in the artery. NO is noise defined as the standard deviation (SD) of signal intensity measured in the subtraction image (of the two non-enhanced scans) at the same location as the arterial ROI is to be measured.</description>
            <units>Ratio</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="23" spread="10"/>
                  <measurement group_id="O2" value="26" spread="11"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Dotarem MRA</title>
          <description>Patients who received a Dotarem enhanced-MRA</description>
        </group>
        <group group_id="E2">
          <title>Gadovist MRA</title>
          <description>Patients who received a Gadovist enhanced-MRA</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Limitation of the study: descriptive study</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Emilie Huchet</name_or_title>
      <organization>Guerbet</organization>
      <phone>+33 1 45 91 50 00 ext 7688</phone>
      <email>emilie.huchet@guerbet-group.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
